Find Academic Supervisors

Tarek MeniawyView profile

Associate Clinical Professor

• Gynaecological Cancers
• Melanoma
• Clinical Trials
• +7 more

Tarek Meniawy serves as a Clinical Associate Professor at the UWA Medical School, University of Western Australia, specializing in Internal Medicine with a focus on oncology. He maintains active clinical appointments at multiple major healthcare institutions across Western Australia. Dr. Meniawy earned his PhD in Immunological Biomarkers of Outcome in Thoracic Cancers from The University of Western Australia (awarded April 26, 2016) and completed his medical degree (MBBS) at Cairo University (awarded October 1, 2000). His research expertise spans Gynaecological Cancers , Melanoma , Clinical Trials , Tumour Immunology , and Immunotherapy . His scholarly fingerprint reveals substantial contributions to Melanoma (100%), Ovarian Cancer (52%), Circulating Tumor DNA (52%), Metastatic Melanoma (40%), Solid Malignant Neoplasm (37%), Nivolumab (37%), Krukenberg Tumor (34%), and Circulating Tumor Cell (33%) research. Dr. Meniawy's recent publications demonstrate his leadership in gynecological oncology and melanoma research, with studies examining homologous recombination deficiency testing, telehealth applications in cancer care, sarcopenia assessment in ovarian cancer patients, and novel therapeutic approaches for endometrial cancer. PARAGON-II: Phase 2 basket study of an Aromatase inhibitor plus PI3KCA inhibitor or CDK4/6 inhibitor in women with hormone receptor positive recurrent/metastatic Gynaecological Neoplasms (Medical Research Future Fund MRFF, 2020-2023) Suzanne Cavanagh ECI Grant - Immunological biomarkers in peripheral blood as a predictor of response to immunotherapy (Cancer Council NSW, 2016) Suzanne Cavanagh ECI Grant - Immunological biomarkers in patients with advanced ovarian cancer treated with schematic chemotherapy (Cancer Council NSW, 2015) With 116 research outputs including 53 articles and 47 abstracts, Dr. Meniawy's work has accumulated 2,598 citations and an h-index of 27. He actively collaborates with researchers across multiple institutions and contributes to high-impact clinical trials in melanoma and gynecological cancers.

Maja KrajinovicView profile

Professor

• Pharmacogenetics
• Pediatric Leukemia
• Hematopoietic Stem Cell Transplantation
• +5 more

Maja Krajinovic is a Full Professor at the University of Montreal’s Faculty of Medicine, affiliated with the Departments of Pediatrics and Pharmacology. She leads the pharmacogenomics laboratory at the Azrieli Research Center of CHU Sainte-Justine. Her research focuses on personalized medicine approaches for pediatric cancers, particularly acute lymphoblastic leukemia (ALL) and hematopoietic stem cell transplantation (HSCT). She holds prestigious awards, including the FRSQ National Researcher Award, and has secured over 36 research grants from agencies like the Canadian Institutes of Health Research and Leukemia & Lymphoma Society of Canada. Education: MD, University of Belgrade (1982) Master’s in Human Genetics (1986) PhD in Molecular Biology (1991) Postdoctoral training in cancer genetics at the International Centre for Genetic Engineering and Biotechnology (Trieste, Italy) and CHU Sainte-Justine Research Interests: Pharmacogenomics of ALL, HSCT complications, microDNA as a biomarker for cancer prognosis, and genetic determinants of drug response. Her lab identified key genetic markers for treatment toxicity and disease recurrence, advancing personalized therapies. Grants & Awards: 36+ funded grants (CIHR, FRQS, CCSRI, etc.) 107+ publications (including 5 book chapters) Labs/Teams: Leads the pharmacogenomics team at CHU Sainte-Justine, collaborating with the GRUM (Genetic Drug Research Group) and Cancer Research Society.

Frederike BokemeyerView profile

Research Fellow

• Psychosocial Oncology
• Health Behavior Analysis
• Cancer Patient Care
• +3 more

Dr. Frederike Bokemeyer holds the position of Research Fellow in the Department of Medical Psychology at the University of Hamburg’s Faculty of Medicine. She is affiliated with the Center for Psychosocial Medicine and works at the W26 building, 3rd floor. Her research focuses on psychosocial aspects of cancer care, particularly smoking cessation strategies and health behavior interventions among oncology patients. She collaborates with interdisciplinary teams to address behavioral determinants impacting cancer outcomes and survivorship care. Her work includes studies on alcohol consumption patterns in cancer patients receiving psycho-oncologic care, healthcare staff experiences with smoking cessation programs, and longitudinal analyses of smoking behavior in breast cancer cohorts. Recent studies emphasize translational research bridging clinical practice and population health. Publications highlight methodological rigor in systematic reviews, meta-analyses, and cross-sectional observational designs. Key contributions include validation of patient satisfaction questionnaires and evaluation of smoking’s prognostic impact on treatment outcomes. Research is published in high-impact journals like *Journal of Cancer Survivorship* and *Preventive Medicine Reports*. Frederike’s expertise spans behavioral oncology, healthcare provider training, and patient-reported outcomes. She contributes to translational research initiatives aiming to integrate behavioral interventions into standard oncology care pathways.

Lindsay CollinView profile

Assistant Professor

• Cancer Epidemiology
• Health Disparities
• Bayesian Analysis
• +5 more

Dr. Lindsay Collin is an Assistant Professor of Epidemiology at Emory University's Rollins School of Public Health. Her research focuses on cancer epidemiology, particularly addressing disparities in cancer outcomes across socioeconomic and racial groups. She specializes in methodological advancements such as Bayesian statistics, bias analysis, and validation study design. Education: BSc, University of British Columbia MPH, Emory University PhD, Emory University Research Interests: Dr. Collin's work examines multilevel predictors of cancer treatment efficacy, recurrence, and mortality. She investigates how social determinants (e.g., neighborhood deprivation, redlining) and molecular factors (e.g., tumor biology) intersect to influence health disparities. Her methodological contributions include improving bias quantification and validation study frameworks. Recent Work Trends: Her recent studies emphasize racial disparities in breast and ovarian cancer outcomes, leveraging geospatial and genomic data. She also explores how systemic factors like historical redlining affect tumor biology and clinical outcomes. Methodologically, her team develops Bayesian approaches to handle measurement error and unmeasured confounding in observational studies. Awards: No specific awards listed, though her work reflects sustained contributions to health equity and epidemiologic methods. Advising & Grants: Advises on studies addressing cancer disparities and methodological rigor. Her grants likely support collaborative projects analyzing large-scale cancer registries and population health datasets. Labs/Teams: Active in Emory's Cancer Research Group and collaborates with Danish cohorts (e.g., ProBe CaRE study). Engages with the Kaiser Permanente Research on Ovarian Cancer Survival (KP-ROCS) initiative.

• Gynecologic Oncology
• Cancer Genetics
• Women’s Health
• +3 more

Dr. Marcia Ciccone is an Clinical Assistant Professor of Obstetrics and Gynecology and Fellowship Program Director for Gynecologic Oncology at the University of Southern California. Her work focuses on women’s health, particularly the genetic basis of gynecologic cancers and multidisciplinary cancer care. She completed her residency and fellowship at USC, emphasizing her commitment to comprehensive, patient-centered oncology care. Her research interests include cancer genetics, targeted therapies, and improving outcomes for patients with endometrial, cervical, and ovarian cancers. Notable contributions include studies on sentinel lymph node biopsy applications, chemoradiation outcomes, and managing adverse effects of immunotherapies like pembrolizumab. Dr. Ciccone’s publications (15+ recent articles) reflect a focus on surgical innovations, clinical trial advancements, and understanding genetic drivers of gynecologic malignancies. She advocates for patient education and long-term relationship-building in oncology care. While no formal awards are listed, her academic role and publication record highlight her expertise in gynecologic oncology. She advises no listed students but contributes to training future clinicians through her fellowship program. Her clinical practice integrates cutting-edge treatments with compassionate care, leveraging USC’s multidisciplinary resources to address complex cases such as placenta accreta spectrum and rare cancer metastases.

• Dermatology
• Skin Pathology
• Medical Imaging Technologies
• +5 more

Marco MANFREDINI is an Associate Professor at the University of Modena and Reggio Emilia, affiliated with the Department of Surgery, Medicine, Dentistry and Morphological Sciences, specializing in Transplantology, Oncology, and Regenerative Medicine. His research focuses on dermatology, autoimmune skin diseases, and advanced imaging technologies such as reflectance confocal microscopy and optical coherence tomography (OCT). He teaches courses in Physiotherapy, Medicine, and Dentistry, emphasizing clinical pathology and systemic diseases. Key research interests include psoriasis management, acne pathogenesis, melanoma diagnostics, and the application of non-invasive imaging in skin cancer. His work bridges translational research and clinical practice, addressing topics like hidradenitis suppurativa, skin aging, and therapeutic efficacy monitoring. Teaching responsibilities span multiple academic programs, integrating didactic lectures with practical case studies to enhance diagnostic and clinical reasoning skills.

• Oncology
• Gynecologic Oncology
• Personalized Medicine
• +3 more

Victoria M. Ettorre is a Clinical Associate Professor at Yale School of Medicine (Yale University) and a Yale Medicine Education & Training Fellow. She holds a Doctor of Osteopathic Medicine (DO) from the Philadelphia College of Osteopathic Medicine, an MS in Biology from New York University, and a BA in Biology from New York University. Her research focuses on gynecologic oncology, particularly in ovarian and endometrial cancers, with an emphasis on personalized treatments, biomarker expression, and clinical trial advancements. She collaborates extensively with researchers like Alessandro Santin, Cem Demirkiran, and Elena Ratner on topics such as targeted therapies and immunotherapy. Her publications span preclinical drug studies, clinical trial analyses, and foundational biology research in developmental systems like C. elegans. Recent work includes evaluating pembrolizumab efficacy in endometrial cancers and exploring mRNA degradation mechanisms in yeast. Her educational background and clinical roles reflect a dual focus on patient care and translational research, bridging basic science and clinical oncology. Collaborative efforts are highlighted through frequent co-authorships and interdisciplinary projects addressing unmet needs in cancer treatment.

• Head and Neck Oncology
• Facial Nerve Reconstruction
• Surgical Oncology
• +3 more

Dr. Hubert Low is a Clinical Associate Professor at the Central Clinical School within the University of Sydney's Faculty of Medicine and Health. His research focuses on head and neck oncology, facial nerve reconstruction, and surgical outcomes in cancer patients. He collaborates extensively with multidisciplinary teams, including surgeons, oncologists, and engineers, to develop novel treatments for facial paralysis and reconstructive challenges. His work spans clinical trials, surgical innovation, and translational research in cancer staging and immunology. Education details are not explicitly provided, but his academic role suggests advanced training in medicine and surgical specialties. Research interests include improving surgical techniques for head and neck cancers, understanding metastatic patterns, and enhancing quality of life through reconstructive interventions. His studies often address nodal staging systems, perineural invasion, and the impact of surgical margins on outcomes. Dr. Low has authored over 100 peer-reviewed articles since 2017, focusing on topics like salivary gland cancer classification, facial nerve paralysis interventions, and genomic analyses of squamous cell carcinoma. He leads projects involving implantable prosthetics for dynamic eye closure and has pioneered the use of ovine models for surgical testing. His work on the Milan System modifications and virtual surgical planning reflects innovation in clinical practice. He advises at least one current PhD student, Aki, focusing on immune predictors in cutaneous SCC. Collaborations include institutions like the ANZ Journal of Surgery and multidisciplinary teams at Sydney's tertiary cancer centers. His clinical practice integrates cutting-edge surgical methods with patient-centered care, addressing complex cases such as osteoradionecrosis and free flap reconstructions. Labs and teams: Active member of Sydney's Head and Neck Cancer Research Group and the Sydney Facial Nerve Clinic. Engaged in projects with biomedical engineers to develop dynamic facial reanimation devices.

• Precision Medicine
• Medical Oncology
• Cancer Research
• +4 more

Giuseppe Badalamenti is an Associate Professor at the University of Palermo's School of Medicine and Surgery, specializing in Precision Medicine within Medical, Surgical and Critical Care Areas. His research focuses on advanced cancer therapies, particularly gastrointestinal stromal tumors (GIST), sarcomas, neuroendocrine tumors, and melanoma. EURACAN European Reference Center in Palermo Medical Oncology Unit affiliation Research Interests: He investigates molecular classification systems, tyrosine kinase inhibitor response/resistance mechanisms, liquid biopsy applications, and multidisciplinary approaches to rare cancers. Publications: Recent work includes studies on Desmoid Fibromatosis (2024), GIST molecular subtyping (2023), liposarcoma therapies (2022), and pancreatic neuroendocrine tumors (2019). Collaborations: Active in the EURACAN network for rare cancer research, with clinical focus on: Sarcoma treatment Liquid biopsy monitoring Immunotherapy toxicity management Neuroendocrine tumor therapies

• Endometrial Cancer
• Uterine Cancer
• Gynecological Oncology
• +3 more

Antonio Gil Moreno is a Professor at the Department of Paediatrics, Obstetrics and Gynaecology, and Preventive Medicine and Public Health at Universitat Autònoma de Barcelona (UAB). His research focuses on gynecological oncology, particularly endometrial and uterine cancers. He has authored over 180 publications and contributes to molecular classification, surgical techniques, and recurrence patterns in cancer. Key collaborations include the PelvEx Collaborative for core outcome sets and the STELLA-2 Randomized Trial. His work aligns with UN Sustainable Development Goals related to health and well-being. Education: Llicenciat (Degree) from UAB (1989). Supervised 22 research works and contributed to datasets like 'Exosome-like vesicles in uterine aspirates.'

Sefer GezerView profile

Professor

• Hematology
• Oncology
• Thrombosis and Coagulation
• +5 more

Sefer Gezer, MD, is a Professor at Rush Medical College, Rush University, within the Department of Internal Medicine, Division of Hematology, Oncology, and Cell Therapy. He serves as the Director of Coagulation and Thrombosis at Rush, highlighting his leadership in this specialized clinical area. His primary clinical expertise lies in deep vein thrombosis, and he practices at the RUSH MD Anderson Cancer Center and its Oak Park location. Dr. Gezer's research interests are deeply rooted in hematology, with a focus on thrombosis and coagulation disorders, antiphospholipid syndrome, myelodysplastic syndromes, and the hematologic implications of infectious diseases like COVID-19. His work bridges clinical practice and research, aiming to improve patient outcomes through a better understanding of blood disorders. His publication record, spanning over two decades, shows a significant contribution to the understanding of thrombotic events in critical illness, particularly during the pandemic. His research trends indicate a consistent focus on clinical hematology, from studying genetic risk factors for bleeding before surgery to exploring novel combination therapies for myelodysplastic syndromes and the impact of blood type on COVID-19 severity. Dr. Gezer received his medical degree from Hacettepe University Faculty of Medicine in Turkey and completed his residency in Hematology at Wayne State University. He is an active member of the faculty, with no indication of retirement or a former staff status. His patient reviews consistently praise his thoroughness, clarity, and compassionate approach to care. His laboratory and team focus is centered on coagulation and thrombosis, operating within the Hematology division at Rush Medical College. He collaborates extensively with other clinicians and researchers, as evidenced by his co-authorship on major clinical studies like the ACTIV-4C trial.

• Cancer Immunology
• Medical Oncology
• Immune Checkpoint Inhibition
• +4 more

Dr. Cor Lamers is a Researcher at Erasmus MC (Medical Center) in the Medical Oncology department. His work bridges immunology and cancer therapy, focusing on T-cell dynamics, immune checkpoint regulation, and innovative treatment strategies. Active in Cancer Immunology Specializes in Immune Checkpoint Inhibition Applies Kinase Activity Profiling for metastatic cancer Recent research trends include CD8 T-cell responses in solid tumors, adenovirus-based therapies for glioblastoma, and blood biomarkers for immunotherapy outcomes. His publications highlight collaborations across oncology, hematology, and pharmaceutical sciences. 2022: Oncolytic adenovirus trials in recurrent GBM 2020: Kinase profiling as immunotherapy predictor 2019: CD8 T-cell biomarkers for nivolumab response While specific awards are not listed here, Lamers' work on cytotoxic T-cell behavior and haploidentical transplantation has informed clinical practices. His supervised work includes unpublished research on immune system dynamics in cancer patients.

• Immunology
• Microbiology
• Infectious Diseases
• +3 more

Jakob Thaning Bay serves as an External Lecturer in the Department of Immunology and Microbiology at the University of Copenhagen, with research spanning immunology, hematology, and infectious diseases. His work focuses on translational applications in chronic lymphocytic leukemia, inflammatory bowel disease, and biomarker discovery for conditions like infectious mononucleosis and meningococcal infections. His research interests emphasize immune system dynamics in disease progression, utilizing genetic epidemiology, microbiome analysis, and large-scale cohort studies. Key areas include the interplay between vascular stress biomarkers and infection history, gut microbiome influences on hematological malignancies, and therapeutic monitoring for biologic treatments in inflammatory conditions. Methodologically, he integrates biobank resources with multi-omics approaches to identify genetic risk factors and treatment response predictors. Recent publications (2022-2025) reveal consistent themes in immune-mediated diseases, with significant contributions to understanding genetic susceptibility in hepatocellular carcinoma, iron deficiency impacts on infection risk in blood donors, and complement system deficiencies in recurrent infections. His work demonstrates strong translational relevance across hematology, oncology, and gastroenterology. Dr. Bay is a core collaborator in the Copenhagen Hospital Biobank initiative's chronic inflammatory disease cohort, particularly for inflammatory bowel disease genetics. His research involves extensive national partnerships including Rigshospitalet and international consortia focused on genetic epidemiology and immune profiling, often leveraging Denmark's national health registries for population-level insights.

• Autoimmune dermatology
• Complex medical dermatology
• Blistering diseases
• +7 more

Dr. Zachary H. Hopkins is an Assistant Professor (Clinical) of Dermatology at the University of Utah, where he also serves as a board-certified dermatologist at multiple clinical locations including the Midvalley Health Center, University of Utah Hospital, and the Veterans Administration Medical Center. He is an active member of the American Academy of Dermatology, the Society for Investigative Dermatology, and the American Dermato-Epidemiology Network. Dr. Hopkins is currently pursuing advanced training in autoimmune dermatology through the University of Utah Autoimmune Dermatology group. Education: M.D., University of Utah School of Medicine Residency in Dermatology, Broward Health Medical Center, Fort Lauderdale, Florida Internship in Preliminary Medicine, University of Utah School of Medicine B.S. in Neuroscience, Brigham Young University Fellowship in Autoimmune and Complex Medical Dermatology, University of Utah Spencer Fox Eccles School of Medicine Research Interests: Dr. Hopkins is a prolific clinical researcher whose work centers on autoimmune skin diseases, including blistering disorders such as pemphigus and pemphigoid, connective tissue diseases like cutaneous lupus and dermatomyositis, and complex leg ulcers. He is particularly invested in improving patient-reported outcome measures (PROMs) to capture health-related quality of life in dermatologic conditions. His epidemiologic interests include leveraging large datasets to understand disease burden and treatment patterns, as well as promoting rigorous research methodology across dermatology. Scientific Contributions & Trends: Across more than 30 peer-reviewed publications, Dr. Hopkins has advanced the understanding of autoimmune dermatoses, validated PROMs such as Skindex-16, and highlighted gaps in clinical practice such as inappropriate topical combination therapy use. His 2025 publications emphasize resilience, psychodermatology, and refinement of immunohistochemistry for melanoma detection, illustrating a trajectory toward precision medicine and holistic patient care. Advising & Grant Activity: While specific trainee names are not listed, Dr. Hopkins’s extensive co-authorship network—including residents, fellows, and faculty—indicates active mentoring within the University of Utah Department of Dermatology. His participation in national conferences further supports his role in educating the next generation of dermatologists. Labs & Teams: Dr. Hopkins collaborates closely with the University of Utah Autoimmune Dermatology group and the Dermatology PRO (Patient-Reported Outcomes) Consortium, fostering interdisciplinary research that bridges clinical care, translational science, and quality-improvement initiatives.

William YongView profile

Professor

• Neuropathology
• Brain Cancer Research
• Biobanking
• +5 more

William Yong, MD is Professor of Pathology and Laboratory Medicine at the David Geffen School of Medicine, University of California, Los Angeles. He serves as Chief of Neuropathology, Director of the UCLA Brain Tumor Translational Resource, and Director of the UCLA Neuropathology Fellowship Program. His clinical expertise encompasses brain and pituitary tumors, neuromuscular pathology, and international telepathology consultations for complex brain cases. Bachelor's in Molecular Biology, UC Berkeley Master's in Biology (Cellular and Molecular), San Francisco State University Medical degree with Honors thesis, UCLA Pathology training, Massachusetts General Hospital/Harvard Medical School Neuropathology fellowship, UCLA Former Director of Neuropathology at Cedars-Sinai Medical Center Dr. Yong's research focuses on biobanking methods, end-stage immunopathology in brain cancer patients, and collaborations spanning AIDS, stroke, dementia, and epilepsy. His team conducts studies in bioinformatics, nanotechnology, non-invasive imaging, neuroradiology, and targeted therapies. He consults for the National Neurologic AIDS Brain Bank and works closely with UCLA Neurosurgery and Neuro-oncology physicians. His publication record demonstrates significant contributions to understanding glioma immunology, tumor microenvironment dynamics, molecular biomarkers in brain cancer, and novel imaging techniques. Research trends indicate strong emphasis on translational applications of neuropathological findings to improve brain tumor diagnostics and therapeutics. Golden Apple Award for teaching Johnny Mercer Foundation Research Award for Brain Cancer American Association of Neuropathologists Lucien J. Rubinstein Award in Neuro-oncology Dr. Yong actively mentors junior faculty, teaches medical and dental students, and supervises pathology, neuropathology, neurosurgery, and neurology residents and fellows. His clinical work includes international telepathology consultations and molecular testing of brain tumor samples. He directs the UCLA Brain Tumor Translational Resource and Neuropathology Fellowship Program, facilitating research collaborations across multiple disciplines. His laboratory work centers on the Brain Tumor Translational Resource, which bridges clinical neuropathology with translational research in brain cancer. The team collaborates extensively with neuro-oncology, neurosurgery, and basic science researchers to develop novel diagnostic and therapeutic approaches for brain tumors.